Treatment of non–small-cell lung cancer with erlotinib or gefitinib
VD Cataldo, DL Gibbons, R Pérez-Soler… - … England Journal of …, 2011 - Mass Medical Soc
Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib | NEJM Skip to main content
NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a …
NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a …
A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer
T Kobayashi, T Koizumi, T Agatsuma, M Yasuo… - Cancer chemotherapy …, 2012 - Springer
Purpose There is as yet no optimal treatment regimen for patients with epidermal growth
factor receptor (EGFR) gene wild-type non-small-cell lung cancer (NSCLC) that has …
factor receptor (EGFR) gene wild-type non-small-cell lung cancer (NSCLC) that has …
Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancer
Y Togashi, K Masago, S Fujita, Y Hatachi, A Fukuhara… - Lung cancer, 2011 - Elsevier
PURPOSE: The maximum tolerated dose (MTD) of erlotinib (150mg) is the approved daily
dose. In contrast, the approved daily dose of gefitinib (250mg) is only one-third of its MTD …
dose. In contrast, the approved daily dose of gefitinib (250mg) is only one-third of its MTD …
[HTML][HTML] Prospective assessment of continuation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of …
N Yoshimura, K Okishio, S Mitsuoka, T Kimura… - Journal of Thoracic …, 2013 - Elsevier
Introduction: Patients with epidermal growth factor receptor (EGFR) mutation positive non–
small-cell lung cancer exhibited marked response to gefitinib or erlotinib. In most cases …
small-cell lung cancer exhibited marked response to gefitinib or erlotinib. In most cases …
[HTML][HTML] EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer
T Fong, D Morgensztern, R Govindan - Journal of Thoracic Oncology, 2008 - Elsevier
Tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR), erlotinib
and gefitinib, are active agents in the treatment of advanced non-small cell lung cancer …
and gefitinib, are active agents in the treatment of advanced non-small cell lung cancer …
Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations
JY Wu, SG Wu, CH Yang, YL Chang, YC Chang… - Lung cancer, 2011 - Elsevier
INTRODUCTION: Erlotinib and gefitinib are tyrosine kinase (TK) inhibitors of epidermal
growth factor receptor (EGFR) that are effective in treating non-small cell lung cancer …
growth factor receptor (EGFR) that are effective in treating non-small cell lung cancer …
Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non–small-cell lung cancer in the …
GM Clark, DM Zborowski, P Santabárbara, K Ding… - Clinical lung cancer, 2006 - Elsevier
Background Erlotinib is an oral, reversible inhibitor of the HER1/epidermal growth factor
receptor (EGFR) tyrosine kinase. A survival advantage for erlotinib compared with placebo …
receptor (EGFR) tyrosine kinase. A survival advantage for erlotinib compared with placebo …
A phase I/II study of weekly high‐dose erlotinib in previously treated patients with nonsmall cell lung cancer
DT Milton, CG Azzoli, RT Heelan… - … Journal of the …, 2006 - Wiley Online Library
BACKGROUND. Preclinical studies have suggested that erlotinib at high doses may inhibit
additional sites downstream of the epidermal growth factor receptor (EGFR), resulting in …
additional sites downstream of the epidermal growth factor receptor (EGFR), resulting in …
[HTML][HTML] Erlotinib in previously treated non–small-cell lung cancer
FA Shepherd, J Rodrigues Pereira… - New England journal …, 2005 - Mass Medical Soc
Background We conducted a randomized, placebo-controlled, double-blind trial to
determine whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival …
determine whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival …
Gefitinib in advanced non-small cell lung cancer: does it deserve a second chance?
TE Stinchcombe, MA Socinski - The Oncologist, 2008 - academic.oup.com
Abstract Learning Objectives After completing this course, the reader will be able to: Discuss
the data on the patient populations enrolled and the efficacy of erlotinib and gefitinib in the …
the data on the patient populations enrolled and the efficacy of erlotinib and gefitinib in the …